Company: INDP
Filing Date: 2025-09-02
Form Type: S-1
Source: 0001493152-25-012531
Chunk: 13

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-09-02
Form: S-1
Chunk 13
---
 accompanying common warrants each
to purchase one share of our common stock being sold in this offering (the last reported sale price per share of our common stock on
the Nasdaq Capital Market on August 27, 2025) and our pro forma as adjusted net tangible book value per share as of June 30,
2025, if you purchase shares of common stock in this offering, you will suffer immediate and substantial dilution of approximately
$1.992 per share in the net tangible book value of the common stock, after deducting placement agent fees and estimated offering
expenses payable by us. See the section titled “Dilution” in this prospectus for a more detailed discussion of the dilution
you will incur if you purchase securities in this offering. The description in this paragraph assumes no sale of pre-funded warrants,
which, if sold, would reduce the number of shares of common stock that we are offering on a one-for-one basis until such pre-funded warrants
are exercised.

If you purchase our securities in this offering, you may experience future dilution as a result of future equity offerings or other equity issuances.

In order to raise additional capital, we believe that we will offer and issue additional shares of our common stock or other securities convertible into or exchangeable for our common stock in the future. We are generally not restricted from issuing additional securities, including shares of common stock, securities that are convertible into or exchangeable for, or that represent the right to receive, common stock or substantially similar securities other than the lock-up agreement. As a result of the dilution in net tangible book value to investors purchasing securities in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of the liquidation of our company. The issuance of securities in future offerings may cause further dilution to our stockholders, including investors in this offering. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in this offering.

In addition, we have a number of stock options and warrants outstanding. To the extent that outstanding stock options or warrants have been or